Enlivex (ENLV) Other Non-Current Assets (2013 - 2025)
Enlivex (ENLV) posted quarterly Other Non-Current Assets of $951000.0 for Q4 2025, down 11.04% year-over-year from $1.1 million in Q4 2024, and down 5.93% quarter-over-quarter from $1.0 million in Q3 2025.
Enlivex (ENLV) Other Non-Current Assets (2013 - 2025) Analysis & Trends
Enlivex's Other Non-Current Assets history runs 13 years deep, the most recent figure standing at $951000.0 for Q4 2025.
- In Q4 2025, Other Non-Current Assets fell 11.04% year-over-year to $951000.0; the TTM figure through Dec 2025 stood at $951000.0 (down 11.04% YoY), while the FY2025 annual figure was $951000.0, down 11.04% from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $951000.0, down from $1.0 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $6.2 million in Q3 2021, with the low at $665000.0 in Q2 2021.
- The 5-year median for Other Non-Current Assets is $1.6 million (2023), against an average of $3.2 million.
- The sharpest annual moves came in 2021 and 2024: Other Non-Current Assets soared 861.76% in 2021, then slumped 76.84% in 2024.
- Enlivex's Other Non-Current Assets stood at $6.2 million in 2021, then dropped by 11.94% to $5.4 million in 2022, then plunged by 71.9% to $1.5 million in 2023, then tumbled by 30.04% to $1.1 million in 2024, then declined by 11.04% to $951000.0 in 2025.
- Business Quant data shows ENLV's Other Non-Current Assets at $951000.0 in Q4 2025, $1.0 million in Q3 2025, and $784000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | 951,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 951,000.00 |
| Sep 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 784,000.00 |
| Mar 31, 2025 | 820,000.00 |
| Dec 31, 2024 | 1.07 Mn |
| Sep 30, 2024 | 1.69 Mn |
| Jun 30, 2024 | 1.28 Mn |
| Mar 31, 2024 | 1.37 Mn |
| Dec 31, 2023 | 1.53 Mn |
| Sep 30, 2023 | 5.71 Mn |
| Jun 30, 2023 | 5.51 Mn |
| Mar 31, 2023 | 5.36 Mn |
| Dec 31, 2022 | 5.44 Mn |
| Sep 30, 2022 | 5.67 Mn |
| Jun 30, 2022 | 5.77 Mn |
| Mar 31, 2022 | 6.03 Mn |
| Dec 31, 2021 | 6.17 Mn |
| Sep 30, 2021 | 6.21 Mn |
| Jun 30, 2021 | 665,000.00 |
| Mar 31, 2021 | 703,000.00 |